Cassava Sciences (SAVA): Net earnings per share (EPS TTM)

Graphic logo of Cassava Sciences Inc (SAVA)

Cassava Sciences, Inc. (SAVA) is integrating ESG principles into the development of Alzheimer's treatments while adhering to bioethics. Earnings per share over the last four quarters demonstrate capital accumulation phases, where -2.22 expresses the current value of the metric. The success of high-risk trials will provide the company with pricing power. However, regulatory investigations regarding Simufilam data pose serious threats to the patient base.

Cassava Pharma (SAVA) - Earnings per share for the last twelve months from 07/04/2022 to 03/11/2026

Analytical breakdowns for Cassava Pharma (SAVA)

- current quotes and average value forecast:
Fundamental company analysis:Cassava Sciences Inc (SAVA)
Flagship merchandise of Cassava

Net income per share over 12 months represents the company's total earnings distributed across all outstanding securities. This metric determines the actual efficiency of the business by excluding the impact of capital dilution. For Cassava Sciences, Inc. (SAVA), the commercial success of simufilam will be the key driver for growth in this figure. The net income per share trend over the last four quarters reflects a transition from a cost-intensive development phase to the monetization of neurotherapy. Investors should view this trend as an indicator of the asset's fundamental stability.

Competitor analysis

biogen.com - Net earnings per share (EPS TTM)|Earnings per share for the trailing year NBIX (Neurocrine)|RGC: Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months Axsome Therapeutics Inc|ACAD (ACADIA Corp) - Net earnings per share (EPS TTM)|XENE: Earnings per share for the trailing year|Net earnings per share for the last 12 months VKTX (Viking Therapeutics, Inc.)|Net earnings per share (EPS TTM) Supernus Pharmaceuticals, Inc. (SUPN)|Catalyst Pharmaceuticals, Inc. - Net earnings per share for the last 12 months|Earnings per share for the last four quarters DNLI (Denali Therapeutics Inc)|Harmony Biosciences - Net earnings per share (EPS TTM)|Earnings per share for the trailing year BHVN (biohavenpharma.com)|AMLX: Net earnings per share (EPS TTM)|Trevi Therapeutics, Inc. - Earnings per share for the trailing year|PRAX (Praxis Corp) - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Anavex Life Sciences AVXL|Net earnings per share (EPS TTM) CBLL|PRTA (prothena.com) - Earnings per share for the trailing year|Net earnings per share (EPS TTM) ALEC (Alector Inc.)|Net earnings per share (EPS TTM) Annexon Biosciences ANNX|Omeros Corporation - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Neurogene Therapeutics NGNE|ACIU: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months Voyager Therapeutics, Inc. (VYGR)|Net earnings per share for the last 12 months NMRA|Net earnings per share for the last 12 months Scilex Holding (SCLX)|Net earnings per share (EPS TTM) TVGN|Net earnings per share for the last 12 months Alpha Cognition Inc ACOG|cogrx.com - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Inhibikase Therapeutics, Inc. IKT|Assertio Holdings - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters Coya Therapeutics COYA|VTGN: Net earnings per share (EPS TTM)|Earnings per share for the last 12 months OVID|Earnings per share for the last twelve months Acumen Pharmaceuticals|CRVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) ATHE|CLNN - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months PepGen Inc PEPG|Net earnings per share for the last four quarters jupiterneurosciences.com (JUNS)|Relmada Therapeutics, Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ANVS (annovisbio.com)|Grace Tx (GRCE) - Earnings per share for the last twelve months|Firefly Neuroscience (AIFF) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months Klotho Neurosciences Inc|neurosense-tx.com (NRSN) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Reviva Pharmaceuticals Holdings, Inc. (RVPH)|Net earnings per share (EPS TTM) MetaVia, Inc. (MTVA)|NeurAxis, Inc - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Helius Medical HSDT|PASG - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Neuphoria Therapeutics, Inc.|Minerva Neurosciences Inc (NERV) - Earnings per share for the last twelve months|Athira Pharma, Inc. - Earnings per share for the trailing year|ADXN (Addex) - Net earnings per share (EPS TTM)|Alzamend Neuro, Inc. - Earnings per one share for the last 12 months|Net earnings per share (EPS TTM) CYCN|PTIX - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months pasitheaclinics.com KTTA|Earnings per share for the trailing year CRGT|Avenue Therapeutics Inc - Net earnings per share (EPS TTM)|Brainstorm Cell Therapeutics, Inc. (BCLI) - Net earnings per share for the last 12 months|CARA: Net earnings per share (EPS TTM)|Chromocell - Earnings per share for the trailing year|ELYM (Eliem Therapeutics, Inc.) - Net earnings per share (EPS TTM)|ITCI (intracellulartherapies.com) - Earnings per share for the last four quarters|Earnings per share for the last twelve months Longboard Pharma (LBPH)|Marinus - Earnings per share for the last 12 months|Net earnings per share (EPS TTM) NKGN (nkgenbiotech.com)|NeuroBo Pharma - Earnings per share for the last twelve months|Sage Therapeutics Inc. - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SNPX (Synaptogenix, Inc.)|TRVN (trevena.com) - Net earnings per share for the last 12 months|Net earnings per share for the last 12 months Vigil Neuroscience Inc.|Earnings per share for the last twelve months Anew Medical|CERE: Earnings per share for the trailing year